SGLT-2 抑制剂治疗非酒精性脂肪性肝病：综述。
SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review.
机构信息
Center for Endocrine Metabolism and Immune Diseases, Lu He Hospital, Capital Medical University, 100000 Beijing, China.
Beijing Key Laboratory of Diabetes Research and Care, 100000 Beijing, China.
出版信息
Front Biosci (Landmark Ed). 2023 Jul 6;28(7):134. doi: 10.31083/j.fbl2807134.
Non-alcoholic fatty liver disease (NAFLD) is a group of metabolic liver illnesses that lead to accumulation of liver fat mainly due to excessive nutrition. It is closely related to insulin resistance, obesity, type 2 diabetes, and cardiovascular disease, and has become one of the main causes of chronic liver disease worldwide. At present, there is no specific drug for the treatment of NAFLD; lifestyle interventions including dietary control and exercise are recommended as routine treatments. As a drug for the treatment of type 2 diabetes, sodium-glucose co-transporter type 2 (SGLT-2) inhibitors may also play a beneficial role in the treatment of NAFLD. This article reviews the mechanism of SGLT-2 inhibitors in the treatment of NAFLD.
非酒精性脂肪性肝病（NAFLD）是一组代谢性肝病，主要由于营养过剩导致肝脏脂肪堆积。它与胰岛素抵抗、肥胖、2 型糖尿病和心血管疾病密切相关，已成为全球慢性肝病的主要病因之一。目前，尚无针对 NAFLD 的特效药物；推荐包括饮食控制和运动在内的生活方式干预作为常规治疗。作为治疗 2 型糖尿病的药物，钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂可能在治疗 NAFLD 方面也发挥有益作用。本文就 SGLT-2 抑制剂治疗 NAFLD 的作用机制进行综述。
Zotero 插件